NeuroMetrix - NURO Stock Forecast, Price & News

NeuroMetrix's stock was trading at $5.02 on January 1st, 2022. Since then, NURO shares have decreased by 68.4% and is now trading at $1.5850.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, January 26th 2023.
View our NURO earnings forecast.

NeuroMetrix, Inc. (NASDAQ:NURO) released its quarterly earnings data on Thursday, October, 20th. The medical device company reported ($0.23) earnings per share (EPS) for the quarter. The medical device company earned $1.97 million during the quarter. NeuroMetrix had a negative net margin of 57.46% and a negative trailing twelve-month return on equity of 20.37%.

Shares of NeuroMetrix reverse split before market open on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 11th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

10 employees have rated NeuroMetrix Chief Executive Officer Shai N. Gozani on Glassdoor.com. Shai N. Gozani has an approval rating of 57% among the company's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI), Palatin Technologies (PTN), Citigroup (C), Salesforce (CRM), Nokia Oyj (NOK), Ampio Pharmaceuticals (AMPE), ReWalk Robotics (RWLK), Aurora Cannabis (ACB), Advanced Micro Devices (AMD) and Vaxart (VXRT).

NeuroMetrix trades on the NASDAQ under the ticker symbol "NURO."

NeuroMetrix's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.51%), Citadel Advisors LLC (0.45%) and Renaissance Technologies LLC (0.36%). Insiders that own company stock include Shai Gozani, Thomas T Higgins and Topline Capital Management, Ll.
View institutional ownership trends.

Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NURO stock can currently be purchased for approximately $1.59.

NeuroMetrix (NASDAQ:NURO) has a market capitalization of $12.29 million and generates $8.25 million in revenue each year. The medical device company earns $-2,280,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

NeuroMetrix's mailing address is 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801. The official website for the company is www.neurometrix.com. The medical device company can be reached via phone at (781) 890-9989, via email at neurometrix.ir@neurometrix.com, or via fax at 302-636-5454.